Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence
In prostate cancer, androgen receptor (AR)–targeting agents are very effective in various
disease stages. However, therapy resistance inevitably occurs, and little is known about how
tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics
analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide
monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical
trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a …
disease stages. However, therapy resistance inevitably occurs, and little is known about how
tumor cells adapt to bypass AR suppression. Here, we performed integrative multiomics
analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide
monotherapy from patients with high-risk prostate cancer enrolled in a neoadjuvant clinical
trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors toward a …
以上显示的是最相近的搜索结果。 查看全部搜索结果